sle e p apne a
play

Sle e p Apne a T he No t so Sile nt Kille r Dominic A. Munafo, - PowerPoint PPT Presentation

Sle e p Apne a T he No t so Sile nt Kille r Dominic A. Munafo, Jr., M.D., F.ABSM Chief Medical Officer T odays Goals Wha t is o b struc tive sle e p a pne a (OSA) Unde rsta nd dia g no sis a nd tre a tme nt Unde rsta nd


  1. Sle e p Apne a… T he No t so Sile nt Kille r Dominic A. Munafo, Jr., M.D., F.ABSM Chief Medical Officer

  2. T oday’s Goals  Wha t is o b struc tive sle e p a pne a (OSA)  Unde rsta nd dia g no sis a nd tre a tme nt  Unde rsta nd the b a sic pa tho physio lo g y  K no w thre e c o nditio ns hig hly a sso c ia te d with OSA

  3. What is Obstr uc tive Sle e p Apne a (OSA) I nsidio us c o nditio n o f re pe titive pa rtia l o r c o mple te a irwa y c o lla pse during sle e p F re que ntly a ssoc ia te d with: o b e sity • dia b e te s • he a rt dise a se •

  4. T he Obstr uc te d Air way

  5. um o f Dise a se Spe c tr • Sno ring • Uppe r Airwa y Re sista nc e Syndro me - (UARS) • Sle e p Apne a – Ob struc tive – Ce ntra l • Ob e sity Hypo ve ntila tio n Syndro me - (OHS)

  6. Pulmo na ry Dise a se a nd Obe sity Obesity Simple Obesity Obesity Hypoventilation Eucapnic Exercise intolerance Hypercapnic Frequent OSA Dyspnea on exertion Frequent OSA Likely increased Increased post-op risk Abnormal respiratory drive 1. pneumonia respiratory drive 2. atelectasis

  7. Sc ope o f the Pro b le m • 20 - 30 millio n Ame ric a ns • Wisc o nsin sle e p c o ho rt study – 626 sub je c ts a g e 30-60 – AHI > 5 in 9% o f wo me n – AHI > 5 in 24% o f me n Yo ung T , N E ng l J Me d 1993;328

  8. Sc ope o f the Pro b le m • OSA Pr e vale nc e in othe r dise ase state s – Ob e sity – 75% – T ype I I DM – 72% (mo de ra te & se ve re – 66%) – Hype rte nsio n – 50 to 75% – CAD & A. F ib . – 50% – CHF – 50 to 75% – De pre ssio n – 40 to 45%

  9. Obstr uc tive Sle e p Apne a • Most c ommon symptoms – L o ud sno ring – Witne sse d a pne a – E xc e ssive da ytime sle e pine ss – Wa king up c ho king & g a sping – Co g nitive impa irme nt

  10. Obstr uc tive Sle e p Apne a Most c ommon signs • – Ob e sity – Ne c k size ≥ 17 men ≥ 16 women – Na so pha ryng e a l na rro wing – Ma xillo -ma ndib ula r a no ma lie s – Hype rte nsio n – Stro ke – He a rt fa ilure

  11. How to Diagnose Ob struc tive Sle e p Apne a Clinic a l suspic io n • Co nsiste nt sig ns a nd sympto ms • Ove rnig ht sle e p study lo o king • fo r re spira to ry e ve nts (HST o r PSG)

  12. Wha t a re Re spir ator y E ve nts Apne a – no a irflo w ≥ 10 seconds Hypopne a – reduced airflow ≥ 10 se c o nds, usua lly a sso c ia te d with o xyg e n de sa tura tio n o r e vide nc e o f a ro usa l

  13. Diagnosing OSA

  14. Co nse q ue nc e s o f Untre a te d OSA Wo lk, R. e t a l. Circ ula tio n 2003;108:9-12

  15. Co nse q ue nc e s o f Untre a te d OSA L e ung , e t a l. Am J Re spirCrit Ca re Me d 2001;164:2147-65

  16. Co nse q ue nc e s o f Untre a te d OSA 0 - 50 0 150 200 150 Baseline Phenylephrine OSA Calculation of LV transmural pressures 150 - 0 = 150 200 - 0 = 200 150 - (- 50) = 200

  17. Co nse q ue nc e s o f Untre a te d OSA 0 - 50 + 10 150 200 150 Phenylephrine – α 1 agonist CPAP = 10 OSA Calculation of LV transmural pressures 150 - 10 = 140 200 - 0 = 200 150 - (- 50) = 200

  18. E ffe c ts o f the Supine Position • V/ Q misma tc h • Shunting • L ung b a se s we ll pe rfuse d b ut po o rly ve ntila te d • Re duc e d lung vo lume s

  19. E ffe c ts o f the Supine Position Pra c tic a l c o nse q ue nc e • during g e ne ra l a ne sthe sia – Mo re ra pid de c line in o xyg e n sa tura tio n during a pne a , < 2 minute s vs. 6 minute s whe n b re a thing 100% o xyg e n

  20. ity Sc ale o f OSA Se ve r • Apne a Hypopne a Inde x - (AHI) – Mild sle e p a pne a - 5 – 15 e ve nts / ho ur – Mo de ra te sle e p a pne a - 16 – 30 e ve nts / ho ur – Se ve re sle e p a pne a - > 30 e ve nts / ho ur • Who to T re a t ? – AHI ≥ 30 5 - 29 ⇒ if sympto ma tic o r if c o -mo rb iditie s pre se nt – AHI

  21. Co nse q ue nc e s o f Untre a te d OSA OSA is assoc iate d with: No c turna l b lo o d pre ssure e le va tio n • • I nde pe nde nt risk fa c to r fo r hype rte nsio n Cha ng e s in L V g e o me try a nd func tio n • Me ta b o lic Syndro me •

  22. Ultima te Conse que nc e s I nc re a sing pre va le nc e o f c hildho o d o b e sity a nd it’ s c o mplic a tio ns c o uld a c tua lly re sult in the c urre nt g e ne ra tio ns o f c hildre n living le ss we ll and fo r a time tha n pre vio us g e ne ra tio ns sho r te r * Da nie ls, F uture Child. 2006 Spring ;16(1):47-67

  23. e atme nt Options fo r OSA T r • Pe rma ne nt we ig ht lo ss • Co ntinuo us po sitive a irwa y pre ssure (CPAP) • Ora l a pplia nc e s • Ora l a nd/ o r ma xillo -fa c ia l surg e rie s • T ra c he o sto my

  24. CPAP T he r apy for OSA Applie d via na sa l ma sk • Ac ts a s pne uma tic splint • Co mplia nc e limits utility • Ma sk fit c ruc ia l •

  25. T ha nk Yo u! L e ar n Mo r e and Visit Us at Sle e pData.c o m

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend